MDMA, or ecstasy, may be efficacious in reducing symptoms of PTSD

Given that the efficacy of serotonin-reuptake inhibitors for post-traumatic stress disorder (PTSD) is limited, a group of researchers explored the use of MDMA.

Granted an FDA Breakthrough Therapy designation for its purported potential to effectively treat symptoms of mental illness, a study published in Nature Medicine considers the use of ecstasy for treating PTSD.

MDMA purportedly functions through its targeting of the serotonin system, possibly alleviating a host of symptoms, like severe anxiety, panic attacks, insomnia, nightmares, and flashbacks.

As part of the phase 3 randomized clinical trial, 90 participants received MDMA for a span of 18 weeks, to test for its efficacy against PTSD.

Researchers tracked for adverse reactions throughout the entire duration of the study.

According to the findings: “These data indicate that, compared with manualized therapy with inactive placebo, MDMA-assisted therapy is highly efficacious in individuals with severe PTSD, and treatment is safe and well-tolerated, even in those with comorbidities.”

“We conclude that MDMA-assisted therapy represents a potential breakthrough treatment that merits expedited clinical evaluation,” author Jennifer Mitchel and her colleagues concluded in their findings.

Image courtesy of iStock
More Stories
Excessive daytime sleepiness may contribute to Alzheimer’s disease